Simultaneous inhibition of DNA-PK and Polϴ improves integration efficiency and precision of genome editing
2023 · Nature Communications · 109 citations
https://doi.org/10.1038/s41467-023-40344-4
M
Mike Firth
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
40
Papers
1.8K
Citations
18
h-index
26
i10-index
Mike Firth is an academic researcher from AstraZeneca (United Kingdom). The author has contributed to research in topics: CRISPR and Genetic Engineering & RNA regulation and disease & Advanced biosensing and bioanalysis techniques. The author has an h-index of 18, co-authored 34 publications.
Papers by this author
worksCRISPR GUARD protects off-target sites from Cas9 nuclease activity using short guide RNAs
2020 · Nature Communications · 75 citations
https://doi.org/10.1038/s41467-020-17952-5
Customizable virus-like particles deliver CRISPR–Cas9 ribonucleoprotein for effective ocular neovascular and Huntington’s disease gene therapy
2025 · Nature Nanotechnology · 50 citations
https://doi.org/10.1038/s41565-024-01851-7
Universal toxin-based selection for precise genome engineering in human cells
2021 · Nature Communications · 49 citations
https://doi.org/10.1038/s41467-020-20810-z
Harnessing DSB repair to promote efficient homology-dependent and -independent prime editing
2022 · Nature Communications · 48 citations
https://doi.org/10.1038/s41467-022-28771-1
Optimized prime editing of the Alzheimer’s disease-associated APOE4 mutation
2024 · Stem Cell Reports · 14 citations
https://doi.org/10.1016/j.stemcr.2024.11.002
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat